Institut Pasteur

Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

The Government of the United States of America As Represented by the Secretary of the Deptartment of Health and Human Services

Institute Pasteur

Agence Nationale De Valorisation De La Recherche (anvar)

Institut National De La Recherche Scientifique

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

Transgene S.a.

Cnrs

Agence Nationale De Valorisation De La Recherche

Genetic Systems Corporation

Institut Pasteur and Centre National De La Recherche Scientifique

Luc Montagnier

Marc Alizon

Pierre Sonigo

Francois Clavel

Denise Guetard

Mireille Guyader

Solange Chamaret

Jean-Claude Chermann

Simon Wain-Hobson

Christine Rouzioux

Francoise Brun-Vezinet

Francoise Barre-Sinoussi

Bernard Krust

Willy Rozenbaum

Francoise Rey

Charles Dauguet

Claudine Axler-Blin

Jacqueline Gruest

Ara G Hovanessian

Robert C Gallo

Mikulas Popovic

Marie-Therese Nugeyre

Mangalasseril G Sarngadharan

Maurice Moncany

Denise Geutard

Pierre Tiollais

Christine Katlama

Marianne Rey

Marie-Anne Rey

Anne G Laurent

Fran&ccedil;ois Clavel

François Clavel

Francedillaois Clavel

Francoise Barre Sinoussi

Pierre Charneau

Stewart T Cole

Emile R Bisagni

Marie-Paule Kieny

Marc Girard

Jean-Pierre Lecocq

Christian Rivalle

Francoise Wendling

Pierre Tambourin

Guy Rautmann

Andrew Borman

Jacques Gruest, Legal Representative

Caroline Quillent

Francoise Vezinet-Brun

Francois Brun-Vezinet

Jacqueline Donjon De Saint-Martin

Marie-Theresa Nugeyre

Simon Wain Hobson

Claire Ducrocq

Fran&ccedil;oise Brun-Vezinet

Anne G Laurent-Crawford

Oliver Danos

Jacques Cohen

Henri Agut

Helene Collandre

Jean-Marie Bechet

Anne Marie Di Rienzo

Alain Blanchard

Veronique Rame

Marie-Anne Rey-Cuillé

Denise Gu&eacute;tard

David Klatzmann

Wesley Loren Cosand

Robert C Nowinski

Robert M Fauve

Olivier Danos

Claude Granier

Jean Igolen

Raymond L Houghton

Tam Huynh Dinh

Catherine Gouyette

Yvette Henin

Stephane Ferris

Jacques H M Cohen

Marie-Anne Rey Cuill&eacute;

Anne G Laurent Crawford

Marie-Anne Rey Cuille

Francedillaoise Brun-Vezinet

Jean C Chermann

Marie Theresa Nugeyre

Herve Rochat

El M Bahraoui

Jurphaar V Rietschoten

Jean-Marc Sabatier

Olivier Schwartz

Francedillaoise Rey

Francoise Vezinet-Bruil

Francedillaoise Barre-Sinoussi

Alain Civier

Rosette Lidereau

Dominique Dormont

Bruno Spire

G Sarngadharan

Mangalasseril G Sarngadhar

Andrew J Watson

Françoise Brun-Vezinet

A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.

Detection of DNA sequences as risk factors for HIV infection

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.

Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.

Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV)

An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognized by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.

Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens

This invention encompasses an env nucleic acid product produced by a process comprising providing a sample containing HIV-1 nucleic acid and amplifying the nucleic acid using primer pairs.

[object Object]

A variant of a LAV virus, designated LAVand capable of causing AIDS. The cDNA and antigens of the LAVvirus can be used for the diagnosis of AIDS and pre-AIDS.

The invention relates to polypeptide fragments of HIV-1, HIV-2, and SIV, antibodies that bind to the polypeptides of the invention, methods of using the antibodies, and kits containing the antibodies. The invention also relates to polynucleotides that encode the polypeptide fragments of the invention.

The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.

HIV-1 DNA fragments that hybridize to genomic HIV-1DNA

Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity

Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing. The gp300 is useful for detecting antibodies to HIV-2 antigens in human body fluids and for raising antibodies to gp300.

Immunogenic compositions comprising human immunodeficiency virus type 2 (HIV-2) glycosylated and unglycosylated envelope proteins and their methods of preparation

The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.

HIV-2 antigen compositions

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

Growing community of inventors

Le Plessis Robinson, France

Luc Montagnier